Genedata has announced its collaboration with Tokyo Medical University, AMR Inc., and Leica Microsystems in a proteomics research initiative aiming at the identification of metastatic biomarkers for the discovery and validation of new protein drug targets.
In the project, proteins extracted from lung and endocrine carcinoma FFPE tissue collections are analyzed using MS-based proteomic methodologies. Formalin-fixed and paraffin-embedded (FFPE) tissue samples have been collected and annotated in hospitals around the globe, representing a resource to study the progression of diseases in detail.
For the downstream molecular analysis, Genedata provides Expressionist, its enterprise system for biomarker discovery, along with professional services. The high-throughput capabilities for quality assessment, pre-processing and integrated analysis make Genedata Expressionist a choice to handle the breadth and complexity of the mass-spectrometry based proteomics data, leading to the detection of molecular effects and interactions that would have otherwise gone unnoticed.
Professor Toshihide Nishimura, Department of Surgery, Tokyo Medical University, and Senior Advisor, Expression Pathology Inc. (USA), said: “Genedata`s support for our proteomics ‘star alliance’ is proving to be of outstanding value. Genedata Expressionist, as a capable high-throughput solution for proteomics analysis, is the key to unlocking a treasure chest of clinical samples for metastatic biomarker research that were intractable before.”
“We are very pleased with our unique contribution,” said Dr. Frank Staubli, Representative Director of Genedata KK in Japan. “MS-based retrospective proteomics represents an opportunity as well as a challenge for an integrated data processing and analysis system. Genedata Expressionist`s performance exceeds our expectations, and shows great potential for the scope of the collaboration.”